Drug intelligence / Profile preview

JW2202

Development stage: Unknown
Lead developer: Jewim Pharmaceuticals
Modality: Small Molecules
Administration: Inhalation

Overview

JW2202 is an investigational inhaled chemical-drug combination product developed by Shandong Jingwei Pharmaceutical for maintenance treatment of chronic obstructive pulmonary disease, including patients with chronic bronchitis and/or pulmonary emphysema. It is supplied as an orally inhaled dry-powder formulation and has progressed to Phase III evaluation in China. Public reporting characterizes JW2202 as a long-acting muscarinic antagonist and long-acting beta-2 adrenergic agonist bronchodilator combination, although the exact active ingredients have not been explicitly identified in the primary registry material reviewed.

Other names: JW 2202JW2202JW-2202

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)CHRM3 (M3)

Beyond the preview

Go deeper on JW2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW2202.

Explore the full profile